Drug Resistance Updates

Papers
(The H4-Index of Drug Resistance Updates is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance304
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment188
Anticancer drug resistance: An update and perspective169
Antimicrobial peptides for combating drug-resistant bacterial infections163
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming163
The role of alternative splicing in cancer: From oncogenesis to drug resistance149
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance128
Hypoxia as a driver of resistance to immunotherapy119
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification118
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies117
Novel nanomedicines to overcome cancer multidrug resistance115
Therapeutic strategies to overcome taxane resistance in cancer115
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy110
Overcoming cancer chemotherapy resistance by the induction of ferroptosis83
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses81
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function76
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects74
Current therapy and drug resistance in metastatic castration-resistant prostate cancer74
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs73
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade69
Long non-coding RNA mediated drug resistance in breast cancer63
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance62
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance61
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance60
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers58
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine56
Impact of cancer metabolism on therapy resistance – Clinical implications55
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer53
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer52
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer52
Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci51
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy50
N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells50
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition50
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms49
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology49
COVID-19 update: The race to therapeutic development45
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents44
Cross-resistance and drug sequence in prostate cancer44
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma40
0.046595096588135